

October 17, 2023

BrightPath to Update the Preclinical Data of HER2-CAR-T and iPSC-derived CAR-iNKT at SITC 2023

Tokyo, Japan - October 17, 2023/ -- BrightPath Biotherapeutics (TSE Growth 4954), a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutics, today announced that Company will present preclinical data on HER2-CAR-T cells and iPSC-derived CAR-iNKT cells at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2023, November 1-5, San Diego). Summary of the abstracts and the electronic posters will be posted on the website of BrightPath after SITC 2023 is held.

- PiggyBac transposon-mediated HER2-CAR-T cells exert anti-tumor efficacy against cholangiocarcinoma. (Abstract number 303)
- iPSC-derived CAR-iNKT cells targeting HER2 show prolonged tumor control and promote durable survival in a tumor xenograft model. (Abstract number 315)

Date & Time: 9 a.m.-9 p.m. EST on Saturday, November 4, 2023

About BrightPath:

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immuno-therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies currently in clinical trials, immunomodulatory antibodies and new drug targeted at cancer specific neoantigens. For more information, visit www.brightpathbio.com

Investor and Media Contact:

irpr@brightpathbio.com

www.brightpathbio.com